Search
Returning search results with filters:
Remove filter for
Category: Health products
Remove filter for
Issue: Health products
Clear all
Search filters
Type
Audience
Category
Issue
Last updated
Recall class
Displaying 1 - 15 of 1046 items.
PMS-Duloxetine 60 mg: Exceeds acceptable interim intake limit for N-nitroso-duloxetine (NDLX)
RecallHealth product recall | 2024-04-17
PMS-Duloxetine 30 mg: Exceeds acceptable interim intake limit for N-nitroso-duloxetine (NDLX)
RecallHealth product recall | 2024-04-17
REDDY-SAPROPTERIN: Affected lot recalled due to potential for unexpected colour change
RecallHealth product recall | 2024-04-17
I-131 Diagnostic Capsule: Affected lots may have decreased thyroid uptake.
RecallHealth product recall | 2024-04-17
Recall of one lot of JAMP Guanfacine XR 4 mg tablets due to contamination with foreign matter
AlertPublic advisory | 2024-04-12
JAMP-Guanfacine XR 4 mg: Foreign matter
RecallHealth product recall | 2024-04-10
Unauthorized health products seized from Vanette Keast Health Consulting in Red Deer, Alberta may pose serious health risks
AlertPublic advisory | 2024-04-09
Unauthorized sexual enhancement products may pose serious health risks
AlertPublic advisory | 2024-04-08
Honeywell Eyesaline Emergency Eyewash: deficiencies in Good Manufacturing Practices (GMP)
RecallHealth product recall | 2024-04-04
JAMP-Rabeprazole 20 mg: Affected lot may contain JAMP-Rabeprazole 10 mg
RecallHealth product recall | 2024-04-02
Unauthorized skin lightening and skin treatment products may pose serious health risks
AlertPublic advisory | 2024-03-27
Ezetrol (ezetimibe) and the Risks of Drug-Induced Liver Injury and Severe Cutaneous Adverse Reactions
AlertHealth professional risk communication | 2024-03-27
Viatrexx Ki-Diab: Incorrect medicinal ingredient
RecallHealth product recall | 2024-03-25
JAMP CEPHALEXIN SUSPENSION: Suspendability out of specification
RecallHealth product recall | 2024-03-21
Only use authorized nicotine pouches as directed, and do not use unauthorized nicotine pouches
AlertPublic advisory | 2024-03-20